NCT04973280View on ClinicalTrials.gov

Study to Evaluate Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs)

CompletedOBSERVATIONAL
Enrollment

187

Participants

Timeline

Start Date

July 26, 2021

Primary Completion Date

July 21, 2022

Study Completion Date

July 21, 2022

Conditions
Myelodysplastic SyndromesBeta-thalassemia
Trial Locations (4)

Unknown

Local Institutions, Vienna

Local Institutions, Brussels

Local Institutions, Berlin

Local Institutions, Rome

Sponsors

Lead Sponsor

Celgene
All Listed Sponsors
lead

Celgene

INDUSTRY

NCT04973280 - Study to Evaluate Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs) | Biotech Hunter | Biotech Hunter